Stocklytics Platform
Asset logo for symbol GLTO
Galecto
GLTO52
$3.01arrow_drop_up1.80%$0.05
Penny Stock
Asset logo for symbol GLTO
GLTO52

$3.01

arrow_drop_up1.80%

Performance History

Chart placeholder
Key Stats
Open$2.90
Prev. Close$2.96
EPS-19.11
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.85M
PE Ratio-
LOWHIGH
Day Range2.87
3.04
52 Week Range2.11
23.50
Ratios
Revenue-
EBITDA Margin %-
EPS-19.11

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Galecto (GLTO)

Galecto Inc (GLTO) is a biotechnology company focused on the development of novel treatments for fibrosis and cancer. The company is headquartered in Boston, Massachusetts, and was founded in 2011. Galecto's lead product candidate is GB0139, an inhaled galectin-3 inhibitor that is being evaluated for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. IPF is a chronic and progressive lung disorder characterized by scarring of the lung tissue, which leads to difficulty in breathing and a decline in lung function. Currently, there are limited treatment options for IPF, and the prognosis is poor. Galecto's GB0139 has shown promising results in preclinical studies and is currently in phase 2 clinical trials.
Galecto's approach to targeting fibrosis is based on the understanding that galectins, a family of proteins, play a critical role in the progression of fibrotic diseases. Galecto's galectin-3 inhibitor has the potential to disrupt the fibrotic processes, leading to the improvement of lung function in IPF patients. In addition to IPF, Galecto is also exploring the potential of its galectin-3 inhibitor in other fibrotic diseases, such as non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc).
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Hans T. Schambye M.D., Ph.D.
Headquarters
Copenhagen
Employees
45
Exchange
NASDAQ
add Galecto  to watchlist

Keep an eye on Galecto

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Galecto 's (GLTO) price per share?

The current price per share for Galecto (GLTO) is $3.02. The stock has seen a price change of $0.05 recently, indicating a 1.81% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Galecto (GLTO)?

For Galecto (GLTO), the 52-week high is $23.5, which is 679.44% from the current price. The 52-week low is $2.11, the current price is 42.82% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Galecto (GLTO) a growth stock?

Galecto (GLTO) has shown an average price growth of -1.65% over the past three years. It has received a score of 94 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Galecto as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Galecto (GLTO) stock price performance year to date (YTD)?

As of the latest data, Galecto (GLTO) has a year-to-date price change of -35.16%. Over the past month, the stock has experienced a price change of 12.5%. Over the last three months, the change has been -33%. Over the past six months, the figure is -46.35%.
help

Is Galecto (GLTO) a profitable company?

Galecto (GLTO) has a net income of -$38.35M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$39.9M. Furthermore, the EBITDA is -$20.1M.
help

What is the market capitalization of Galecto (GLTO)?

Galecto (GLTO) has a market capitalization of $3.85M. The average daily trading volume is 2.94, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level